Is SYMQY or JEPQ a better dividend investment in 2026?

SYMQY currently yields 358.49% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: SYMQY offers higher current income.

What is the dividend yield difference between SYMQY and JEPQ?

SYMQY has a forward dividend yield of 358.49% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 347.39 percentage points.

Home › Compare › SYMQY vs JEPQ

SYMQY vs JEPQ: Dividend Comparison 2026

SYMQY yields 358.49% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SYMQY wins by $5189.29M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SYMQY

● Live price

358.49%

Share price

$0.56

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$5189.33M

Annual income

$3,350,688,442.05

Full SYMQY calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — SYMQY vs JEPQ

📍 SYMQY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SYMQY	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SYMQY + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SYMQY pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYMQY

Annual income on $10K today (after 15% tax)

$30,471.41/yr

After 10yr DRIP, annual income (after tax)

$2,848,085,175.74/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, SYMQY beats the other by $2,848,083,346.04/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYMQY + JEPQ for your $10,000?

SYMQY: 50%JEPQ: 50%

100% JEPQ50/50100% SYMQY

Portfolio after 10yr

$2594.69M

Annual income

$1,675,345,297.31/yr

Blended yield

64.57%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYMQY buys

JEPQ buys

No recent congressional trades found for SYMQY or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSYMQYJEPQ

Forward yield	358.49% ✓	11.10%
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$5189.33M ✓	$44.8K
Annual income after 10y	$3,350,688,442.05 ✓	$2,152.59
Total dividends collected	$5014.82M ✓	$16.3K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: SYMQY vs JEPQ ($10,000, DRIP)

Year	SYMQY Portfolio	SYMQY Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$46,549	$35,848.72	$11,930	$1,110.39	+$34.6K → SYMQY
2	$205,762	$155,954.38	$14,133	$1,224.34	+$191.6K → SYMQY
3	$864,438	$644,273.43	$16,632	$1,340.46	+$847.8K → SYMQY
4	$3,454,575	$2,529,625.76	$19,454	$1,457.97	+$3.44M → SYMQY
5	$13,144,248	$9,447,852.61	$22,626	$1,576.08	+$13.12M → SYMQY
6	$47,660,569	$33,596,224.50	$26,175	$1,694.09	+$47.63M → SYMQY
7	$164,846,065	$113,849,255.31	$30,133	$1,811.32	+$164.82M → SYMQY
8	$544,400,504	$368,015,214.66	$34,531	$1,927.17	+$544.37M → SYMQY
9	$1,718,361,020	$1,135,852,481.39	$39,403	$2,041.08	+$1718.32M → SYMQY
10	$5,189,334,734	$3,350,688,442.05	$44,787	$2,152.59	+$5189.29M → SYMQY

SYMQY vs JEPQ: Complete Analysis 2026

SYMQY — Stock

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.

Full SYMQY Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this SYMQY vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYMQY vs SCHD SYMQY vs JEPI SYMQY vs O SYMQY vs KO SYMQY vs MAIN SYMQY vs XYLD SYMQY vs QYLD SYMQY vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.